article
21 June 2021 | By IRBM Science park
With over 20 years’ of expertise in phage display, IRBM applies its extensive peptide and antibody libraries to discover lead therapeutic candidates. Dr Licia Tomei, Director of Display Technologies, IRBM, discusses the company’s phage display capabilities and how they accelerate the drug discovery process.